Baird Medical Accelerates U.S. Expansion in Interventional Thyroidology at NASIT 2026
MWN-AI** Summary
Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD), a leader in minimally invasive Microwave Ablation (MWA) technology, announced a significant advancement in its U.S. expansion at the 2026 North American Society for Interventional Thyroidology (NASIT) held in Portland, Oregon. The event showcased Baird Medical's proprietary MWA platforms during a thermal ablation workshop, capturing considerable interest among attendees. The company utilized this opportunity to engage in critical discussions with Key Opinion Leaders (KOLs) and emerging physicians, emphasizing the clinical applications of their advanced technology.
Mark Saxton, U.S. CEO of Baird Medical, highlighted the event’s importance by stating that their presence at NASIT aims to enhance the standard of care in the U.S. healthcare system. By connecting with both seasoned pioneers and new specialists in the field, Baird Medical aims to promote the adoption of MWA therapies, which empower healthcare providers to deliver superior, minimally invasive treatment options.
Baird Medical is committed to advancing patient outcomes through innovative technology, focusing on developing surgical robotic systems and minimally invasive surgical instruments. The company’s FDA 510(k) certification indicates its readiness for broader clinical applications, with its solutions being utilized in over 30 renowned hospitals and clinics across the U.S., including prestigious institutions like Mayo Clinic and UCSF Medical Center. As a market leader in China for thyroid microwave ablation devices, Baird Medical is also expanding its presence globally, emphasizing its commitment to strategic collaborations.
In summary, Baird Medical's active participation at NASIT 2026 reflects its ambitious goal to enhance access to advanced interventional thyroidology treatments and showcases its commitment to innovative healthcare solutions.
MWN-AI** Analysis
Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) has made significant strides in expanding its U.S. market presence in the interventional thyroidology sector, as highlighted during its recent showcase at the 2026 NASIT conference. With its cutting-edge Microwave Ablation (MWA) technology, the company is positioning itself at the forefront of minimally invasive treatments, which are increasingly demanded by both healthcare providers and patients alike.
The company’s strategic engagement with Key Opinion Leaders (KOLs) and emerging specialists during NASIT is a smart maneuver, as these relationships can facilitate broader adoption of their technology. Furthermore, as healthcare trends continue to gravitate towards non-invasive procedures, Baird Medical's focus on precision-based therapies aligns with current patient care standards. This context bodes well for future revenue growth, particularly if they successfully secure FDA approvals or additional partnerships.
Investors should closely monitor Baird Medical's initiatives in strategic collaborations and its ability to maintain a leading market position in both the U.S. and China, where it already has a strong foothold. The company’s diverse international presence, already spanning over 20 countries, further emphasizes its potential for scalability and resilience against market fluctuations.
However, caution is advised. The potential risks outlined in their forward-looking statements, including regulatory challenges and economic conditions, warrant scrutiny. These factors could impact revenue projections and operational stability.
In conclusion, Baird Medical presents a compelling investment opportunity amidst its ongoing efforts to innovate and upgrade patient care standards through MWA technology. Investors should evaluate the company's execution of its strategic plans while remaining mindful of the associated risks. Keeping abreast of their performance in upcoming quarters will be crucial for making informed investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
NEW YORK, March 9, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced its successful strategic showcase at the 2026 North American Society for Interventional Thyroidology (NASIT) in Portland, Oregon. This engagement advances the Company's goal to expand patient access to advanced, minimally invasive treatment options.
Baird Medical's proprietary MWA platforms garnered significant interest during the event's thermal ablation workshop and at the Company's dedicated exhibit. Leadership facilitated targeted discussions with established Key Opinion Leaders (KOLs) and emerging physicians, exchanging critical insights on the clinical applications of MWA technology. Through these interactions, the Company showcased how integrating precision, non-surgical interventions into modern treatment paradigms can elevate the standard of patient care.
"Our robust presence at NASIT directly advances our mission to elevate the standard of care across the United States," stated Mark Saxton, U.S. CEO of Baird Medical. "By connecting with established pioneers and new specialists at the forefront of thermal ablation, we are accelerating the adoption of precision therapies and empowering providers to deliver superior, minimally invasive outcomes."
About Baird Medical
Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across the United States, including Mayo Clinic, Tulane Medical Center, Columbia University Medical Center, UCSF Medical Center, Weill Cornell Medical Center, and The George Washington University Hospital. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.
Forward-Looking Statements
This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.
Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (6) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC.
The foregoing list of factors is not exclusive. Additional information concerning certain of these, and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com
SOURCE BDMD
FAQ**
How does Baird Medical Investment Holdings Ltd (BDMD) plan to leverage its recent showcase at NASIT 2026 to enhance its market presence in the U.S. interventional thyroidology sector?
What specific strategies is Baird Medical Investment Holdings Ltd (BDMD) employing to foster collaborations with key opinion leaders and academic institutions as part of its expansion efforts?
In what ways does Baird Medical Investment Holdings Ltd (BDMD) anticipate that its minimally invasive Microwave Ablation technology will change the standard of care for thyroid conditions in the United States?
What measures is Baird Medical Investment Holdings Ltd (BDMD) implementing to mitigate the risks associated with its U.S. expansion and ensure successful adoption of its technologies in the healthcare market?
**MWN-AI FAQ is based on asking OpenAI questions about Baird Medical Investment Holdings Ltd (NASDAQ: BDMD).
NASDAQ: BDMD
BDMD Trading
-4.73% G/L:
$2.62 Last:
582,472 Volume:
$2.75 Open:
